nach oben

Current Allergy and Asthma Reports

Erschienen in:

01.08.2015 | Basic and Applied Science (PJ Bryce, Section Editor)

Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism

verfasst von: Michael B. Fessler

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Four decades ago, it was observed that stimulation of T cells induces rapid changes in cellular cholesterol that are required before proliferation can commence. Investigators returning to this phenomenon have finally revealed its molecular underpinnings. Cholesterol trafficking and its dysregulation are now also recognized to strongly influence dendritic cell function, T cell polarization, and antibody responses. In this review, the state of the literature is reviewed on how cholesterol and its trafficking regulate the cells of the adaptive immune response and in vivo disease phenotypes of dysregulated adaptive immunity, including allergy, asthma, and autoimmune disease. Emerging evidence supporting a potential role for statins and other lipid-targeted therapies in the treatment of these diseases is presented. Just as vascular biologists have embraced immunity in the pathogenesis and treatment of atherosclerosis, so should basic and clinical immunologists in allergy, pulmonology, and other disciplines seek to encompass a basic understanding of lipid science.

Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9:125–38.PubMed

Marcel YL, Ouimet M, Wang MD. Regulation of cholesterol efflux from macrophages. Curr Opin Lipidol. 2008;19:455–61.PubMed

Fessler MB, Parks JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol. 2011;187:1529–35.PubMedCentralPubMed

Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, et al. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation. 2009;119:2367–75.PubMed

Klingenberg R, Gerdes N, Badeau RM, Gistera A, Strodthoff D, Ketelhuth DF, et al. Depletion of Foxp3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest. 2013;123:1323–34.PubMedCentralPubMed

Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA, et al. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science. 2007;316:285–8.PubMed

Heikkila HM, Trosien J, Metso J, Jauhiainen M, Pentikainen MO, Kovanen PT, et al. Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation. J Cell Biochem. 2010;109:615–23.PubMed

Robertson AK, Zhou X, Strandvik B, Hansson GK. Severe hypercholesterolaemia leads to strong Th2 responses to an exogenous antigen. Scand J Immunol. 2004;59:285–93.PubMed

Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998;101:1717–25.PubMedCentralPubMed

10.

Shamshiev AT, Ampenberger F, Ernst B, Rohrer L, Marsland BJ, Kopf M. Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J Exp Med. 2007;204:441–52.PubMedCentralPubMed

11.

Maganto-Garcia E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation. 2011;124:185–95.PubMedCentralPubMed

12.

Kolbus D, Ramos OH, Berg KE, Persson J, Wigren M, Bjorkbacka H, et al. CD8+ T cell activation predominate early immune responses to hypercholesterolemia in apoE (−)(/)(−) mice. BMC Immunol. 2010;11:58.PubMedCentralPubMed

13.

Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem. 1991;266:12216–22.PubMed

14.

Chen HW, Heiniger HJ, Kandutsch AA. Relationship between sterol synthesis and DNA synthesis in phytohemagglutinin-stimulated mouse lymphocytes. Proc Natl Acad Sci U S A. 1975;72:1950–4.PubMedCentralPubMed

15.

Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008;134:97–111.PubMedCentralPubMed

16.••

Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol. 2013;14:489–99. The authors demonstrate a critical role for SREBP in blasting of CD8+ T cells as well as clonal expansion of T cells during viral infection.PubMedCentralPubMed

17.

Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T (reg)-cell function. Nature. 2013;499:485–90.PubMedCentralPubMed

18.

Armstrong AJ, Gebre AK, Parks JS, Hedrick CC. ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation. J Immunol. 2010;184:173–83.PubMedCentralPubMed

19.

Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol. 2009;29:843–9.PubMedCentralPubMed

20.

Geyeregger R, Shehata M, Zeyda M, Kiefer FW, Stuhlmeier KM, Porpaczy E, et al. Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes. J Leukoc Biol. 2009;86:1039–48.PubMed

21.

Cui G, Qin X, Wu L, Zhang Y, Sheng X, Yu Q, et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest. 2011;121:658–70.PubMedCentralPubMed

22.

Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, et al. The benzenesulfoamide t0901317 [n-(2,2,2-trifluoroethyl)-n-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethy l]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol Pharmacol. 2010;77:228–36.PubMedCentralPubMed

23.

Solt LA, Kamenecka TM, Burris TP. LXR-mediated inhibition of CD4+ T helper cells. PLoS One. 2012;7:e46615.PubMedCentralPubMed

24.

Walcher D, Vasic D, Heinz P, Bach H, Durst R, Hausauer A, et al. LXR activation inhibits chemokine-induced CD4-positive lymphocyte migration. Basic Res Cardiol. 2010;105:487–94.PubMed

25.

Walcher D, Kummel A, Kehrle B, Bach H, Grub M, Durst R, et al. LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler Thromb Vasc Biol. 2006;26:1022–8.PubMed

26.••

Soroosh P, Wu J, Xue X, Song J, Sutton SW, Sablad M, et al. Oxysterols are agonist ligands of RORgammat and drive Th17 cell differentiation. Proc Natl Acad Sci U S A. 2014;111:12163–8. The authors identify several naturally occurring oxysterols as RORγt agonists and show that they promote Th17 polarization of T cells.PubMedCentralPubMed

27.••

Hu X, Wang Y, Hao L, Liu X, Lesch CA, Sanchez BM, et al. Sterol metabolism controls Th17 differentiation by generating endogenous RORgamma agonists. Nat Chem Biol. 2015;11(2):141–7. The authors report that during Th17 differentiation coordinated changes in cholesterol metabolism lead to accumulation of desmosterol, which functions as a potent endogenous RORγt agonist.PubMed

28.••

Reboldi A, Dang EV, McDonald JG, Liang G, Russell DW, Cyster JG. Inflammation. 25-hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type i interferon. Science. 2014;345:679–84. The authors report that 25‐hydroxycholesterol suppresses production of IL‐1 family cytokines by broading inhibiting inflammasomes.PubMedCentralPubMed

29.

He HT, Lellouch A, Marguet D. Lipid rafts and the initiation of T cell receptor signaling. Semin Immunol. 2005;17:23–33.PubMed

30.

Molnar E, Swamy M, Holzer M, Beck-Garcia K, Worch R, Thiele C, et al. Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering. J Biol Chem. 2012;287:42664–74.PubMedCentralPubMed

31.

Janes PW, Ley SC, Magee AI. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J Cell Biol. 1999;147:447–61.PubMedCentralPubMed

32.

Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science. 1999;283:680–2.PubMed

33.

Chyu KY, Lio WM, Dimayuga PC, Zhou J, Zhao X, Yano J, et al. Cholesterol lowering modulates T cell function in vivo and in vitro. PLoS One. 2014;9:e92095.PubMedCentralPubMed

34.

Surls J, Nazarov-Stoica C, Kehl M, Olsen C, Casares S, Brumeanu TD. Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response. PLoS One. 2012;7:e38733.PubMedCentralPubMed

35.

Cheng HY, Wu R, Gebre AK, Hanna RN, Smith DJ, Parks JS, et al. Increased cholesterol content in gammadelta (gammadelta) T lymphocytes differentially regulates their activation. PLoS One. 2013;8:e63746.PubMedCentralPubMed

36.

Sag D, Wingender G, Nowyhed H, Wu R, Gebre AK, Parks JS, et al. ATP-binding cassette transporter G1 intrinsically regulates invariant Nkt cell development. J Immunol. 2012;189:5129–38.PubMedCentralPubMed

37.

Heine G, Dahten A, Hilt K, Ernst D, Milovanovic M, Hartmann B, et al. Liver X receptors control IgE expression in B cells. J Immunol. 2009;182:5276–82.PubMed

38.

Chen Y, Duan Y, Kang Y, Yang X, Jiang M, Zhang L, et al. Activation of liver X receptor induces macrophage interleukin-5 expression. J Biol Chem. 2012;287:43340–50.PubMedCentralPubMed

39.

Park K, Scott AL. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J Leukoc Biol. 2010;88:1081–7.PubMedCentralPubMed

40.

Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang G, Russell DW. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin a production. Proc Natl Acad Sci U S A. 2009;106:16764–9.PubMedCentralPubMed

41.

Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, et al. Oxysterols direct immune cell migration via EBI2. Nature. 2011;475:524–7.PubMedCentralPubMed

42.

Liu C, Yang XV, Wu J, Kuei C, Mani NS, Zhang L, et al. Oxysterols direct B-cell migration through EBI2. Nature. 2011;475:519–23.PubMed

43.

Pierce SK. Lipid rafts and B-cell activation. Nat Rev Immunol. 2002;2:96–105.PubMed

44.

Gupta N, DeFranco AL. Lipid rafts and B cell signaling. Semin Cell Dev Biol. 2007;18:616–26.PubMedCentralPubMed

45.

Karnell FG, Brezski RJ, King LB, Silverman MA, Monroe JG. Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling. J Biol Chem. 2005;280:25621–8.PubMed

46.

Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol. 2000;1:156–62.PubMed

47.

Hiltbold EM, Poloso NJ, Roche PA. MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol. 2003;170:1329–38.PubMed

48.

Son Y, Kim SM, Lee SA, Eo SK, Kim K. Oxysterols induce transition of monocytic cells to phenotypically mature dendritic cell-like cells. Biochem Biophys Res Commun. 2013;438:161–8.PubMed

49.

Perrin-Cocon L, Coutant F, Agaugue S, Deforges S, Andre P, Lotteau V. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J Immunol. 2001;167:3785–91.PubMed

50.

Zhong L, Yang Q, Xie W, Zhou J. Liver X receptor regulates mouse GM-CSF-derived dendritic cell differentiation in vitro. Mol Immunol. 2014;60:32–43.PubMed

51.

Feig JE, Pineda-Torra I, Sanson M, Bradley MN, Vengrenyuk Y, Bogunovic D, et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest. 2010;120:4415–24.PubMedCentralPubMed

52.

Torocsik D, Barath M, Benko S, Szeles L, Dezso B, Poliska S, et al. Activation of liver X receptor sensitizes human dendritic cells to inflammatory stimuli. J Immunol. 2010;184:5456–65.PubMed

53.

Geyeregger R, Zeyda M, Bauer W, Kriehuber E, Saemann MD, Zlabinger GJ, et al. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin. Blood. 2007;109:4288–95.PubMed

54.

Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I, et al. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun. 2005;338:1126–36.PubMed

55.

Perrin-Cocon L, Diaz O, Carreras M, Dollet S, Guironnet-Paquet A, Andre P, et al. High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation. Immunobiology. 2012;217:91–9.PubMed

56.

Angeli V, Llodra J, Rong JX, Satoh K, Ishii S, Shimizu T, et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity. 2004;21:561–74.PubMed

57.

Yi T, Cyster JG. EBI2-mediated bridging channel positioning supports splenic dendritic cell homeostasis and particulate antigen capture. eLife. 2013;2, e00757.PubMedCentralPubMed

58.

Bosch B, Heipertz EL, Drake JR, Roche PA. Major histocompatibility complex (MHC) class II-peptide complexes arrive at the plasma membrane in cholesterol-rich microclusters. J Biol Chem. 2013;288:13236–42.PubMedCentralPubMed

59.

Roy K, Ghosh M, Pal TK, Chakrabarti S, Roy S. Cholesterol lowering drug may influence cellular immune response by altering MHC II function. J Lipid Res. 2013;54:3106–15.PubMedCentralPubMed

60.

Buatois V, Baillet M, Becart S, Mooney N, Leserman L, Machy P. MHC class II-peptide complexes in dendritic cell lipid microdomains initiate the CD4 TH1 phenotype. J Immunol. 2003;171:5812–9.PubMed

61.

Eren E, Yates J, Cwynarski K, Preston S, Dong R, Germain C, et al. Location of major histocompatibility complex class II molecules in rafts on dendritic cells enhances the efficiency of T-cell activation and proliferation. Scand J Immunol. 2006;63:7–16.PubMed

62.

Wang SH, Yuan SG, Peng DQ, Zhao SP. HDL and apoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis. 2012;225:105–14.PubMed

63.

Kuipers HF, Biesta PJ, Groothuis TA, Neefjes JJ, Mommaas AM, van den Elsen PJ. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol. 2005;66:653–65.PubMed

64.

Kimata H. Cholesterol selectively enhances in vitro latex-specific IgE production in atopic dermatitis patients with latex allergy. Life Sci. 2005;76:1527–32.PubMed

65.

Ouyang F, Kumar R, Pongracic J, Story RE, Liu X, Wang B, et al. Adiposity, serum lipid levels, and allergic sensitization in Chinese men and women. J Allergy Clin Immunol. 2009;123:940–8.PubMedCentralPubMed

66.

Kusunoki T, Morimoto T, Sakuma M, Mukaida K, Yasumi T, Nishikomori R, et al. Total and low-density lipoprotein cholesterol levels are associated with atopy in schoolchildren. J Pediatr. 2011;158:334–6.PubMed

67.

Pesonen M, Ranki A, Siimes MA, Kallio MJ. Serum cholesterol level in infancy is inversely associated with subsequent allergy in children and adolescents. A 20-year follow-up study. Clin Exp Allergy : J Br Soc Allergy Clin Immunol. 2008;38:178–84.

68.

Fessler MB, Jaramillo R, Crockett PW, Zeldin DC. Relationship of serum cholesterol levels to atopy in the US population. Allergy. 2010;65:859–64.PubMedCentralPubMed

69.

Yeh YF, Huang SL. Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation. J Biomed Sci. 2004;11:599–606.PubMed

70.

Chen YC, Tung KY, Tsai CH, Su MW, Wang PC, Chen CH, et al. Lipid profiles in children with and without asthma: interaction of asthma and obesity on hyperlipidemia. Diabetes Metab Syndr. 2013;7:20–5.PubMed

71.

Scichilone N, Rizzo M, Benfante A, Catania R, Giglio RV, Nikolic D, et al. Serum low density lipoprotein subclasses in asthma. Respir Med. 2013;107:1866–72.PubMed

72.

Fenger RV, Gonzalez-Quintela A, Linneberg A, Husemoen LL, Thuesen BH, Aadahl M, et al. The relationship of serum triglycerides, serum HDL, and obesity to the risk of wheezing in 85,555 adults. Respir Med. 2013;107:816–24.PubMed

73.

Cirillo DJ, Agrawal Y, Cassano PA. Lipids and pulmonary function in the third national health and nutrition examination survey. Am J Epidemiol. 2002;155:842–8.PubMed

74.

Yiallouros PK, Savva SC, Kolokotroni O, Dima K, Zerva A, Kouis P, et al. Asthma: the role of low high-density-lipoprotein cholesterol in childhood and adolescence. Int Arch Allergy Immunol. 2014;165:91–9.PubMed

75.

Fessler MB. Next stop for HDL: the lung. Clin Exp Allergy : J Br Soc Allergy Clin Immunol. 2012;42:340–2.

76.

Fessler MB, Massing MW, Spruell B, Jaramillo R, Draper DW, Madenspacher JH, et al. Novel relationship of serum cholesterol with asthma and wheeze in the United States. J Allergy Clin Immunol. 2009;124:967–74. e961-915.PubMedCentralPubMed

77.

Ho WE, Xu YJ, Xu F, Cheng C, Peh HY, Tannenbaum SR, et al. Metabolomics reveals altered metabolic pathways in experimental asthma. Am J Respir Cell Mol Biol. 2013;48:204–11.PubMed

78.

Dai C, Yao X, Keeran KJ, Zywicke GJ, Qu X, Yu ZX, et al. Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factor-dependent mechanism. Am J Respir Cell Mol Biol. 2012;47:186–95.PubMedCentralPubMed

79.

Ekmekci OB, Donma O, Ekmekci H, Yildirim N, Uysal O, Sardogan E, et al. Plasma paraoxonase activities, lipoprotein oxidation, and trace element interaction in asthmatic patients. Biol Trace Elem Res. 2006;111:41–52.PubMed

80.

Nandedkar SD, Weihrauch D, Xu H, Shi Y, Feroah T, Hutchins W, et al. D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res. 2011;52:499–508.PubMedCentralPubMed

81.

Draper DW, Gowdy KM, Madenspacher JH, Wilson RH, Whitehead GS, Nakano H, et al. ATP binding cassette transporter G1 deletion induces IL-17-dependent dysregulation of pulmonary adaptive immunity. J Immunol. 2012;188:5327–36.PubMedCentralPubMed

82.

Wang W, Xu H, Shi Y, Nandedkar S, Zhang H, Gao H, et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res. 2010;51:2560–70.PubMedCentralPubMed

83.

Otera H, Ishida T, Nishiuma T, Kobayashi K, Kotani Y, Yasuda T, et al. Targeted inactivation of endothelial lipase attenuates lung allergic inflammation through raising plasma HDL level and inhibiting eosinophil infiltration. Am J Physiol Lung Cell Mol Physiol. 2009;296:L594–602.PubMed

84.

Fredriksson K, Mishra A, Lam JK, Mushaben EM, Cuento RA, Meyer KS, et al. The very low density lipoprotein receptor attenuates house dust mite-induced airway inflammation by suppressing dendritic cell-mediated adaptive immune responses. J Immunol. 2014;192:4497–509.PubMedCentralPubMed

85.

Yao X, Fredriksson K, Yu ZX, Xu X, Raghavachari N, Keeran KJ, et al. Apolipoprotein e negatively regulates house dust mite-induced asthma via a low-density lipoprotein receptor-mediated pathway. Am J Respir Crit Care Med. 2010;182:1228–38.PubMedCentralPubMed

86.

Yao X, Dai C, Fredriksson K, Lam J, Gao M, Keeran KJ, et al. Human apolipoprotein e genotypes differentially modify house dust mite-induced airway disease in mice. Am J Physiol Lung Cell Mol Physiol. 2012;302:L206–215.PubMedCentralPubMed

87.

Yao X, Dai C, Fredriksson K, Dagur PK, McCoy JP, Qu X, et al. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol. 2011;186:576–83.PubMedCentralPubMed

88.

Shi Y, Xu X, Tan Y, Mao S, Fang S, Gu W. A liver-X-receptor ligand, T0901317, attenuates IgE production and airway remodeling in chronic asthma model of mice. PLoS One. 2014;9:e92668.PubMedCentralPubMed

89.

Fowler AJ, Sheu MY, Schmuth M, Kao J, Fluhr JW, Rhein L, et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Investig Dermatol. 2003;120:246–55.PubMed

90.

Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol. 2010;6:280–9.PubMed

91.

Rothlin CV, Lemke G. Tam receptor signaling and autoimmune disease. Curr Opin Immunol. 2010;22:740–6.PubMedCentralPubMed

92.

N AG, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. 2009;31:245–58.

93.

Chintalacharuvu SR, Sandusky GE, Burris TP, Burmer GC, Nagpal S. Liver X receptor is a therapeutic target in collagen-induced arthritis. Arthritis Rheum. 2007;56:1365–7.PubMed

94.

Hindinger C, Hinton DR, Kirwin SJ, Atkinson RD, Burnett ME, Bergmann CC, et al. Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis. J Neurosci Res. 2006;84:1225–34.PubMed

95.

Xu J, Wagoner G, Douglas JC, Drew PD. Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity. J Leukoc Biol. 2009;86:401–9.PubMedCentralPubMed

96.

Yang H, Zheng S, Qiu Y, Yang Y, Wang C, Yang P, et al. Activation of liver X receptor alleviates ocular inflammation in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2014;55:2795–804.PubMedCentralPubMed

97.

Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol. 2004;173:6366–75.PubMed

98.

Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O. Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem. 1997;272:17551–7.PubMed

99.

Feng H, Guo L, Wang D, Gao H, Hou G, Zheng Z, et al. Deficiency of scavenger receptor BI leads to impaired lymphocyte homeostasis and autoimmune disorders in mice. Arterioscler Thromb Vasc Biol. 2011;31:2543–51.PubMedCentralPubMed

100.

Hamon Y, Chambenoit O, Chimini G. ABCA1 and the engulfment of apoptotic cells. Biochim Biophys Acta. 2002;1585:64–71.PubMed

101.

Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KM, et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther. 2010;12:R93.PubMedCentralPubMed

102.

Morse JH, Witte LD, Goodman DS. Inhibition of lymphocyte proliferation stimulated by lectins and allogeneic cells by normal plasma lipoproteins. J Exp Med. 1977;146:1791–803.PubMed

103.

Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009;60:2870–9.PubMedCentralPubMed

104.

Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003;48:2533–40.PubMed

105.

Azzam KM, Fessler MB. Crosstalk between reverse cholesterol transport and innate immunity. Trends Endocrinol Metab: TEM. 2012;23:169–78.PubMedCentralPubMed

106.

Chen Y, Park YB, Patel E, Silverman GJ. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol. 2009;182:6031–43.PubMedCentralPubMed

107.

Chen Y, Khanna S, Goodyear CS, Park YB, Raz E, Thiel S, et al. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol. 2009;183:1346–59.PubMedCentralPubMed

108.

Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Decreased lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:3955–65.PubMed

109.

Jury EC, Flores-Borja F, Kabouridis PS. Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol. 2007;18:608–15.PubMedCentralPubMed

110.

Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, et al. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol. 2004;172:7821–31.PubMed

111.

Jury EC, Isenberg DA, Mauri C, Ehrenstein MR. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol. 2006;177:7416–22.PubMed

112.

McDonald G, Deepak S, Miguel L, Hall CJ, Isenberg DA, Magee AI, et al. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest. 2014;124:712–24.PubMedCentralPubMed

113.

Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687–92.PubMed

114.

Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78–84.PubMed

115.

Ulivieri C, Baldari CT. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. Pharmacol Res: Off J Ital Pharmacol Soc. 2014;88:41–52.

116.

Ghittoni R, Napolitani G, Benati D, Ulivieri C, Patrussi L, Laghi Pasini F, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol. 2006;36:2885–93.PubMed

117.

Ulivieri C, Fanigliulo D, Benati D, Pasini FL, Baldari CT. Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation. Eur J Immunol. 2008;38:2832–44.PubMed

118.

Arora M, Chen L, Paglia M, Gallagher I, Allen JE, Vyas YM, et al. Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci U S A. 2006;103:7777–82.PubMedCentralPubMed

119.

Dunn SE, Youssef S, Goldstein MJ, Prod’homme T, Weber MS, Zamvil SS, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006;203:401–12.PubMedCentralPubMed

120.

Blank N, Schiller M, Krienke S, Busse F, Schatz B, Ho AD, et al. Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme a reductase without decreasing cholesterol synthesis. J Immunol. 2007;179:3613–21.PubMed

121.

Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res. 2003;93:948–56.PubMed

122.

Hillyard DZ, Cameron AJ, McDonald KJ, Thomson J, MacIntyre A, Shiels PG, et al. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis. 2004;175:305–13.PubMed

123.

Coward W, Chow SC. Effect of atorvastatin on Th1 and Th2 cytokine secreting cells during T cell activation and differentiation. Atherosclerosis. 2006;186:302–9.PubMed

124.

Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, Rickli H, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004;175:83–90.PubMed

125.

Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORc in CD4+ lymphocytes. J Immunol. 2008;180:6988–96.PubMed

126.

Zhang X, Tao Y, Wang J, Garcia-Mata R, Markovic-Plese S. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. Eur J Immunol. 2013;43:281–9.PubMed

127.

Kim YC, Kim KK, Shevach EM. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology. 2010;130:484–93.PubMedCentralPubMed

128.

Maneechotesuwan K, Kasetsinsombat K, Wamanuttajinda V, Wongkajornsilp A, Barnes PJ. Statins enhance the effects of corticosteroids on the balance between regulatory T cells and Th17 cells. Clin Exp Allergy : J Br Soc Allergy Clin Immunol. 2013;43:212–22.

129.

Robinson AJ, Kashanin D, O’Dowd F, Fitzgerald K, Williams V, Walsh GM. Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions. Clin Exp Allergy : J Br Soc Allergy Clin Immunol. 2009;39:1866–74.

130.

Krauth MT, Majlesi Y, Sonneck K, Samorapoompichit P, Ghannadan M, Hauswirth AW, et al. Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy. 2006;61:281–8.PubMed

131.

Schaafsma D, Dueck G, Ghavami S, Kroeker A, Mutawe MM, Hauff K, et al. The mevalonate cascade as a target to suppress extracellular matrix synthesis by human airway smooth muscle. Am J Respir Cell Mol Biol. 2011;44:394–403.PubMed

132.

Schaafsma D, McNeill KD, Mutawe MM, Ghavami S, Unruh H, Jacques E, et al. Simvastatin inhibits TGFbeta1-induced fibronectin in human airway fibroblasts. Respir Res. 2011;12:113.PubMedCentralPubMed

133.

Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol. 2006;35:722–9.PubMed

134.

Chiba Y, Sato S, Misawa M. Inhibition of antigen-induced bronchial smooth muscle hyperresponsiveness by lovastatin in mice. J Smooth Muscle Res = Nihon Heikatsukin Gakkai kikanshi. 2008;44:123–8.PubMed

135.

Kim DY, Ryu SY, Lim JE, Lee YS, Ro JY. Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model. Eur J Pharmacol. 2007;557:76–86.PubMed

136.

McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol. 2004;172:2903–8.PubMed

137.

Zeki AA, Franzi L, Last J, Kenyon NJ. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med. 2009;180:731–40.PubMedCentralPubMed

138.

Imamura M, Okunishi K, Ohtsu H, Nakagome K, Harada H, Tanaka R, et al. Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax. 2009;64:44–9.PubMed

139.

Huang CF, Peng HJ, Wu CC, Lo WT, Shih YL, Wu TC. Effect of oral administration with pravastatin and atorvastatin on airway hyperresponsiveness and allergic reactions in asthmatic mice. Ann Allergy, Asthma Immunol: Off Publ Am Coll Allergy Asthma Immunol. 2013;110:11–7.

140.

Xu L, Dong XW, Shen LL, Li FF, Jiang JX, Cao R, et al. Simvastatin delivery via inhalation attenuates airway inflammation in a murine model of asthma. Int Immunopharmacol. 2012;12:556–64.PubMed

141.

Zeki AA, Bratt JM, Rabowsky M, Last JA, Kenyon NJ. Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling? Transl Res: J Lab Clin Med. 2010;156:335–49.

142.

Silva D, Couto M, Delgado L, Moreira A. A systematic review of statin efficacy in asthma. J Asthma : Off J Assoc Care Asthma. 2012;49:885–94.

143.

Si XB, Zhang S, Huo LY, Dai WL, Wang HL. Statin therapy does not improve lung function in asthma: a meta-analysis of randomized controlled trials. J Int Med Res. 2013;41:276–83.PubMed

144.

Naidoo D, Wu AC, Brilliant MH, Denny J, Ingram C, Kitchner TE, et al. A polymorphism in HLA-G modifies statin benefit in asthma. Pharmacogenomics J. 2015;15:272–7.PubMed

145.

Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358–70.PubMed

146.

McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363:2015–21.PubMed

147.

Lv S, Liu Y, Zou Z, Li F, Zhao S, Shi R, et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2014;33:69–76.PubMed

148.

Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363:1607–8.PubMed

149.

Sena A, Pedrosa R, Graca MM. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol. 2003;250:754–5.PubMed

150.

Gkaliagkousi E, Gavriilaki E, Doumas M, Petidis K, Aslanidis S, Stella D. Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. J Clin Rheumatol: Pract Rep Rheum Musculoskelet Dis. 2012;18:422–30.

151.

Tu H, Li Q, Xiang S, Jiang H, Mao Y, Shou Z, et al. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Atherosclerosis. 2012;222:29–33.PubMed

152.

Lokhandwala T, West-Strum D, Banahan BF, Bentley JP, Yang Y. Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis. BMJ open. 2012;2.

153.

Zeki AA, Oldham J, Wilson M, Fortenko O, Goyal V, Last M, et al. Statin use and asthma control in patients with severe asthma. BMJ open. 2013;3.

154.

Huang CC, Chan WL, Chen YC, Chen TJ, Chou KT, Lin SJ, et al. Statin use in patients with asthma: a nationwide population-based study. Eur J Clin Investig. 2011;41:507–12.

155.

Ostroukhova M, Kouides RW, Friedman E. The effect of statin therapy on allergic patients with asthma. Ann Allergy Asthma Immunol: Off Publ Am Coll Allergy Asthma Immunol. 2009;103:463–8.

156.

Tse SM, Li L, Butler MG, Fung V, Kharbanda EO, Larkin EK, et al. Statin exposure is associated with decreased asthma-related emergency department visits and oral corticosteroid use. Am J Respir Crit Care Med. 2013;188:1076–82.PubMedCentralPubMed

157.

Tse SM, Charland SL, Stanek E, Herrera V, Goldfarb S, Litonjua AA, et al. Statin use in asthmatics on inhaled corticosteroids is associated with decreased risk of emergency department visits. Curr Med Res Opin. 2014;30:685–93.PubMed

158.

Braganza G, Chaudhuri R, McSharry C, Weir CJ, Donnelly I, Jolly L, et al. Effects of short-term treatment with atorvastatin in smokers with asthma—a randomized controlled trial. BMC Pulm Med. 2011;11:16.PubMedCentralPubMed

159.

Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010;126:754–62.PubMed

160.

Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M, Lipworth BJ. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol. 2007;119:328–35.PubMed

161.

Moini A, Azimi G, Farivar A. Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial. Allergy Asthma Immunol Res. 2012;4:290–4.PubMedCentralPubMed

162.

Hothersall EJ, Chaudhuri R, McSharry C, Donnelly I, Lafferty J, McMahon AD, et al. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax. 2008;63:1070–5.PubMed

163.

Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax. 2010;65:891–6.PubMed

Titel: Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism
verfasst von: Michael B. Fessler
Publikationsdatum: 01.08.2015
Verlag: Springer US
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 8/2015
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-015-0548-7

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism

Abstract

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2015

Oral Food Challenges: The Design must Reflect the Clinical Question

Humoral Primary Immunodeficiencies in Chronic Rhinosinusitis

Erratum to: Technological Innovations for High-Throughput Approaches to In Vitro Allergy Diagnosis

The Future of Sublingual Immunotherapy in the United States

Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association

Role of Rhinopharyngoscopy in Diagnosis of Rhinopathies

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO